<DOC>
	<DOCNO>NCT01497808</DOCNO>
	<brief_summary>The primary objective determine maximum tolerate hypofractionated radiotherapy dose ( MTD ) solitary metastatic focus ( 'index lesion ' ) follow ipilimumab , metastatic melanoma patient without brain involvement The secondary objective determine late toxicity , immune-related clinical response immune pharmacodynamic change hypofractionated radiotherapy follow ipilimumab</brief_summary>
	<brief_title>RADVAXâ„¢ : A STRATIFIED PHASE I/II DOSE ESCALATION TRIAL OF HYPOFRACTIONATED RADIOTHERAPY FOLLOWED BY IPILIMUMAB IN METASTATIC MELANOMA</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion Criteria Patient &gt; 18 year old Histologically confirm diagnosis melanoma Previously treat previously untreated metastatic melanoma AJCC stag criterion Presence index lesion &gt; 1 cm amenable hypofractionated radiotherapy least one additional lesion follow response use RECIST criterion ECOG Performance status 0 1 Signed inform consent document Ability tolerate stereotactic body radiation therapy ( e.g . lie flat hold position treatment ) Exclusion Criteria Prior systemic therapy within 14 day study enrollment . Patients must adequately recover prior systemic therapy side effect deem PI . Clinical contraindication stereotactic body radiotherapy ( e.g . active systemic sclerosis , active inflammatory bowel disease bowel within target field , etc ) Presence history central nervous system metastasis ( include brain ) Longterm use systemic corticosteroid Prior RT preclude delivery hypofractionated radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>previously untreated</keyword>
	<keyword>previously treat</keyword>
	<keyword>bone , lung , liver subcutaneous involvement</keyword>
	<keyword>nodal involvement</keyword>
	<keyword>without evidence brain involvement</keyword>
</DOC>